Objective: To evaluate the efficacy and safety of botulinum toxin type A (BTX-A) in treating patients with low bladder compliance (BC) secondary to spinal cord injury (SCI). Methods: From 2011 to 2016, we retrospected patients who received BTX-A injections for LBC secondary to SCI. The primary outcomes were urodynamic parameters including maximum detrusor pressure (Pdetmax), bladder compliance (BC). Related adverse events were recorded. Results: 72 SCI patients were selected (62 males, 10 females, age range 18 - 52 years; mean age 28.5 years). 12 weeks after BTX-A injection, Pdetmax decreased from 51.02 cmH2O to 28.31 cmH2O. BC increased from 3.64 ml/cmH2O to 10.08 ml/cmH2O. 12 patients had mild transient haematuria for 1 - 2 days. Conclusion: Intradetrusor BTX-A injection was effective and safe for patients with low BC secondary to SCI.
References
[1]
Abrams, P., Cardozo, L., Fall, M., et al. (2002) The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourology and Urodynamics, 21, 167-78. https://doi.org/10.1002/nau.10052
[2]
Wyndaele, J.J., Gammie, A., Bruschini, H., De Wachter, S., Fry, C.H., Jabr, R.I., Kirschner-Hermanns, R. and Madersbacher, H. (2011) Bladder Compliance What Does It Represent: Can We Measure It, and Is It Clinically Relevant? Neurourology and Urodynamics, 30, 714-722. https://doi.org/10.1002/nau.21129
[3]
Gerridzen, R.G., Thijssen, A.M., Dehoux, E., et al. (1992) Risk Factors for Upper Tract Deterioration in Chronic Spinal Cord Injury Patients. The Journal of Urology, 147, 416-418. https://doi.org/10.1016/S0022-5347(17)37254-3
[4]
Groen, J., Pannek, J., Castro Diaz, D., Del Popolo, G., Gross, T., Hamid, R., et al. (2016) Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. European Urology, 69, 324-333.
https://doi.org/10.1016/j.eururo.2015.07.071
[5]
Schurch, B., de Seze, M., Denys, P., et al. (2005) Botulinum Toxin Type A Is a Safe and Effective Treatment for Neurogenic Urinary Incontinence: Results of a Single Treatment, Randomized, Placebo Controlled 6-Month Study. The Journal of Urology, 174, 196-200. https://doi.org/10.1097/01.ju.0000162035.73977.1c
[6]
Stöhrer, M., Goepel, M., Kondo, A., Kramer, G., Madersbacher, H., Millard, R., Rossier, A. and Wyndaele, J.J. (1999) The Standardization of Terminology in Neurogenic Lower Urinary Tract Dysfunction: With Suggestions for Diagnostic Procedures. International Continence Society Standardization Committee. Neurourology and Urodynamics, 18, 139-158.
https://doi.org/10.1002/(SICI)1520-6777(1999)18:2<139::AID-NAU9>3.0.CO;2-U
[7]
Schurch, B., Stöhrer, M., Kramer, G., Schmid, D.M., Gaul, G. and Hauri, D. (2000) Botulinum-A Toxin for Treating Detrusor Hyperreflexia in Spinal Cord Injured Patients: A New Alternative to Anticholinergic Drugs? Preliminary Results. The Journal of Urology, 164, 692-697. https://doi.org/10.1016/S0022-5347(05)67283-7
[8]
Wagner, T.H., Patrick, D.L., Bavendam, T.G., et al. (1996) Quality of Life of Persons with Urinary Incontinence: Development of a New Measure. Urology, 47, 67-71.
https://doi.org/10.1016/S0090-4295(99)80384-7
[9]
Wang, S.C., McGuire, E.J. and Bloom, D.A. (1988) A Bladder Pressure Management System for Myelodysplasia—Clinical Outcome. The Journal of Urology, 140, 1499-502. https://doi.org/10.1016/S0022-5347(17)42084-2
